Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL661968 | 1.00 | REN (0.60) | RENCYP3A4 | |
| SCHEMBL5309346 | 0.77 | REN (0.88) | RENCYP3A4 | |
| SCHEMBL5942002 | 0.76 | CYP3A4 (0.85) | RENCYP3A4 | |
| Formic Acid SCHEMBL5941874 | 0.76 | CYP3A4 (0.80) | RENCYP3A4 | |
| SCHEMBL662969 | 0.76 | REN (0.73) | RENCYP3A4 | |
| SCHEMBL3091553 | 0.75 | REN (1.00) | RENCYP3A4 | |
| SCHEMBL3091547 | 0.75 | REN (1.00) | RENCYP3A4 | |
| SCHEMBL660737 | 0.75 | KDM4E (0.46) | CYP3A4 | |
| SCHEMBL660736 | 0.75 | KDM4E (0.46) | CYP3A4 | |
| SCHEMBL662068 | 0.75 | CYP3A4 (0.46) | RENCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046293-A1 | RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2012-02-23 | — | — | US | disclosed |
| US-8063105-B2 | Renin inhibitors | MERCK CANADA INC. (CA) | 2011-11-22 | — | — | US | disclosed |
| US-20090281103-A1 | Renin Inhibitors | MERCK CANADA INC. (CA) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046293-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | REN 1/4885CYP3A4 774/4885 |
| US-20090281103-A1 | Renin Inhibitors | REN, ACE, AGT | REN 1/4885CYP3A4 531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.